Erasca, Inc. Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-03-12: Fiscal year end 2025-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location San Diego, California.
- 2025-03-20: Fiscal year end 2024-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location San Diego, California.
- 2024-03-27: Fiscal year end 2023-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location San Diego, California.
- 2023-03-23: Fiscal year end 2022-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location San Diego, California.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|
| 2026-03-12 | 2025-12-31 | KPMG LLP | 185 | San Diego, California | No |
|---|
| 2025-03-20 | 2024-12-31 | KPMG LLP | 185 | San Diego, California | No |
|---|
| 2024-03-27 | 2023-12-31 | KPMG LLP | 185 | San Diego, California | No |
|---|
| 2023-03-23 | 2022-12-31 | KPMG LLP | 185 | San Diego, California | No |
|---|
| 2022-03-24 | 2021-12-31 | KPMG LLP | 185 | San Diego, California | No |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|